{"protocolSection": {"identificationModule": {"nctId": "NCT02058147", "orgStudyIdInfo": {"id": "EFC12404"}, "secondaryIdInfos": [{"id": "2013-003131-30", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1148-4334", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM", "officialTitle": "A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)", "acronym": "LixiLan-O"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-02"}, "primaryCompletionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-06", "studyFirstSubmitQcDate": "2014-02-06", "studyFirstPostDateStruct": {"date": "2014-02-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-12-16", "resultsFirstSubmitQcDate": "2016-12-16", "resultsFirstPostDateStruct": {"date": "2017-02-10", "type": "ACTUAL"}, "dispFirstSubmitDate": "2016-06-15", "dispFirstSubmitQcDate": "2016-06-15", "dispFirstPostDateStruct": {"date": "2016-06-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-03-31", "lastUpdatePostDateStruct": {"date": "2017-05-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Primary Objective:\n\nTo compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to Week 30.\n\nSecondary Objective:\n\nTo compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin treatment) over a 30 week treatment period in participants with type 2 diabetes.", "detailedDescription": "Approximately 37 weeks including up to 6 weeks of screening, 30-week treatment period, and a 3 days follow-up period."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1170, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)", "type": "EXPERIMENTAL", "description": "FRC once daily (QD) for 30 weeks. Dose individually adjusted.", "interventionNames": ["Drug: Insulin glargine/lixisenatide Fixed Ratio Combination", "Drug: Metformin"]}, {"label": "Insulin Glargine", "type": "ACTIVE_COMPARATOR", "description": "Insulin glargine QD for 30 weeks. Dose individually adjusted.", "interventionNames": ["Drug: Insulin glargine (HOE901)", "Drug: Metformin"]}, {"label": "Lixisenatide", "type": "ACTIVE_COMPARATOR", "description": "Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Insulin glargine/lixisenatide Fixed Ratio Combination", "description": "Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar\u00ae pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.", "armGroupLabels": ["Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)"], "otherNames": ["(HOE901/AVE0010)"]}, {"type": "DRUG", "name": "Insulin glargine (HOE901)", "description": "Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.", "armGroupLabels": ["Insulin Glargine"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "Lixisenatide (AVE0010)", "description": "Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.", "armGroupLabels": ["Lixisenatide"], "otherNames": ["Lyxumia"]}, {"type": "DRUG", "name": "Metformin", "description": "Pharmaceutical form: Tablet; Route of administration: Oral administration.", "armGroupLabels": ["Insulin Glargine", "Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)", "Lixisenatide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in HbA1c From Baseline to Week 30", "description": "Primary outcome was to test superiority of FRC versus Lixisenatide and non-inferiority versus Insulin glargine.\n\nChange in HbA1c was calculated by subtracting baseline value from Week 30 value.", "timeFrame": "Baseline, Week 30"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With HbA1c <7.0% or \u22646.5% at Week 30", "description": "Participants without Week 30 value for HbA1c were counted as non-responders.", "timeFrame": "Week 30"}, {"measure": "Change in Plasma Glucose Excursion From Baseline to Week 30", "description": "Plasma glucose excursion = 2-hour postprandial plasma glucose (PPG) value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 30 value. Missing data was imputed using last observation carried forward (LOCF).", "timeFrame": "Baseline, Week 30"}, {"measure": "Change in Body Weight From Baseline to Week 30", "description": "Change in body weight was calculated by subtracting baseline value from Week 30 value.", "timeFrame": "Baseline, Week 30"}, {"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 30", "description": "Change in FPG was calculated by subtracting baseline value from Week 30 value.", "timeFrame": "Baseline, Week 30"}, {"measure": "Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30", "description": "Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.", "timeFrame": "Baseline, Week 30"}, {"measure": "Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30", "timeFrame": "Week 30"}, {"measure": "Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] \u2264 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period", "description": "Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u226470 mg/dL (3.9 mmol/L).", "timeFrame": "Baseline up to Week 30"}, {"measure": "Average Daily Insulin Glargine Dose at Week 30", "description": "The analysis included scheduled measurements obtained up to the date of last injection of the IMP, including those obtained after introduction of rescue therapy.", "timeFrame": "Week 30"}, {"measure": "Change in 2-Hour Postprandial Plasma Glucose (PPG) From Baseline to Week 30", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 30 value. Missing data was imputed using LOCF.", "timeFrame": "Baseline, Week 30"}, {"measure": "Percentage of Participants Reaching HbA1c <7.0% at Week 30 With No Documented Symptomatic Hypoglycemia (PG \u2264 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period", "description": "Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u226470 mg/dL (3.9 mmol/L). The analysis included all HbA1c measurements at Week 30, including those obtained after the IMP discontinuation or the introduction of rescue medication.", "timeFrame": "Baseline up to Week 30"}, {"measure": "Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period", "description": "Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) was performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8%.", "timeFrame": "Baseline up to Week 30"}, {"measure": "Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year", "description": "Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u2264 70 mg/dL (3.9 mmol/L).", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)"}, {"measure": "Percentage of Participants With Documented Symptomatic Hypoglycemia", "description": "Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u2264 70 mg/dL (3.9 mmol/L).", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)"}, {"measure": "Percentage of Participants With Severe Symptomatic Hypoglycemia", "description": "Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not have been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk of injury to themselves or others.", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Participants with type 2 diabetes mellitus diagnosed for at least 1 year before the screening visit, treated for at least 3 months prior to visit 1 with metformin alone or metformin and a second oral anti-diabetic treatment that could be a sulfonylurea, a glinide, a sodium glucose co-transporter-2 inhibitor or a di-peptidyl peptidase 4 (DPP-4) inhibitors, and who were not adequately controlled with this treatment.\n* Signed written informed consent.\n\nExclusion criteria:\n\n* HbA1c at screening visit:\n\n  * less than 7.5% or more than 10% for participants previously treated with metformin alone,\n  * less than 7.0% or more than 9% for participants previously treated with metformin and a second oral anti-diabetic treatment.\n* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.\n* Use of oral glucose-lowering agents other than those stated in the inclusion criteria or any injectable glucose-lowering agents during the 3 months before screening.\n* Previous Treatment with insulin (except for short-term treatment due to intercurrent illness including gestational diabetes, at the discretion of the trial physician).\n* History of discontinuation of a previous treatment with a glucagon-like peptide (GLP-1) receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.\n* Participant who previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide fixed ratio combination or had previously received lixisenatide.\n* Any contraindication to metformin use, according to local labeling.\n* Use of weight loss drugs within 3 months prior to screening visit.\n* Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.\n* History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.\n* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g, multiple endocrine neoplasia syndromes).\n* Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.\n* At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m\\^2.\n* At screening visit amylase and/or lipase more than 3 times the upper limit of the normal (ULN) laboratory range.\n* At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 3 ULN.\n* At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).\n\nExclusion Criteria for randomization at the end of the screening period:\n\n* HbA1c less than 7% or above 10%;\n* Fasting Plasma glucose above 250 mg/dL (13.9 mmol/L);\n* Metformin maximal tolerated dose less than 1500 mg/day;\n* Amylase and/or lipase more than 3 ULN.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number 840027", "city": "Phoenix", "state": "Arizona", "zip": "85028", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Investigational Site Number 840122", "city": "Phoenix", "state": "Arizona", "zip": "85032", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Investigational Site Number 840062", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Investigational Site Number 840023", "city": "Tempe", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Investigational Site Number 840084", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Investigational Site Number 840100", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Investigational Site Number 840065", "city": "Bell Gardens", "state": "California", "zip": "90201", "country": "United States", "geoPoint": {"lat": 33.96529, "lon": -118.15146}}, {"facility": "Investigational Site Number 840090", "city": "Chino", "state": "California", "zip": "91710", "country": "United States", "geoPoint": {"lat": 34.01223, "lon": -117.68894}}, {"facility": "Investigational Site Number 840002", "city": "Chula Vista", "state": "California", "zip": "91911", "country": "United States", "geoPoint": {"lat": 32.64005, "lon": -117.0842}}, {"facility": "Investigational Site Number 840013", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Investigational Site Number 840053", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Investigational Site Number 840017", "city": "La Jolla", "state": "California", "zip": "92037", "country": "United States", "geoPoint": {"lat": 32.84727, "lon": -117.2742}}, {"facility": "Investigational Site Number 840070", "city": "Lancaster", "state": "California", "zip": "93534", "country": "United States", "geoPoint": {"lat": 34.69804, "lon": -118.13674}}, {"facility": "Investigational Site Number 840121", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Investigational Site Number 840126", "city": "Los Angeles", "state": "California", "zip": "90017", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840044", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840101", "city": "Mission Hills", "state": "California", "zip": "91345", "country": "United States", "geoPoint": {"lat": 34.68952, "lon": -120.4356}}, {"facility": "Investigational Site Number 840086", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Investigational Site Number 840120", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Investigational Site Number 840005", "city": "Northridge", "state": "California", "zip": "91325", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Investigational Site Number 840034", "city": "Palm Springs", "state": "California", "zip": "92262", "country": "United States", "geoPoint": {"lat": 33.8303, "lon": -116.54529}}, {"facility": "Investigational Site Number 840074", "city": "Port Hueneme", "state": "California", "zip": "93041", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -119.19511}}, {"facility": "Investigational Site Number 840068", "city": "San Ramon", "state": "California", "zip": "94583", "country": "United States", "geoPoint": {"lat": 37.77993, "lon": -121.97802}}, {"facility": "Investigational Site Number 840067", "city": "Santa Ana", "state": "California", "zip": "92704", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"facility": "Investigational Site Number 840029", "city": "Tarzana", "state": "California", "zip": "91356", "country": "United States", "geoPoint": {"lat": 34.17334, "lon": -118.55397}}, {"facility": "Investigational Site Number 840006", "city": "Temecula", "state": "California", "zip": "92591", "country": "United States", "geoPoint": {"lat": 33.49364, "lon": -117.14836}}, {"facility": "Investigational Site Number 840078", "city": "West Hills", "state": "California", "zip": "91345", "country": "United States", "geoPoint": {"lat": 34.19731, "lon": -118.64398}}, {"facility": "Investigational Site Number 840059", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Investigational Site Number 840038", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840104", "city": "Bradenton", "state": "Florida", "zip": "34208", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Investigational Site Number 840098", "city": "Miami", "state": "Florida", "zip": "33156-7563", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Investigational Site Number 840014", "city": "New Port Richey", "state": "Florida", "zip": "34652", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "Investigational Site Number 840047", "city": "Ocoee", "state": "Florida", "zip": "34761", "country": "United States", "geoPoint": {"lat": 28.56917, "lon": -81.54396}}, {"facility": "Investigational Site Number 840056", "city": "Palm Harbor", "state": "Florida", "zip": "34684", "country": "United States", "geoPoint": {"lat": 28.07807, "lon": -82.76371}}, {"facility": "Investigational Site Number 840089", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Investigational Site Number 840054", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Investigational Site Number 840119", "city": "Woodstock", "state": "Georgia", "zip": "30189", "country": "United States", "geoPoint": {"lat": 34.10149, "lon": -84.51938}}, {"facility": "Investigational Site Number 840108", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Investigational Site Number 840075", "city": "Arlington Heights", "state": "Illinois", "zip": "60005", "country": "United States", "geoPoint": {"lat": 42.08836, "lon": -87.98063}}, {"facility": "Investigational Site Number 840080", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site Number 840026", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site Number 840116", "city": "Chicago", "state": "Illinois", "zip": "60616", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site Number 840050", "city": "Springfield", "state": "Illinois", "zip": "62704", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Investigational Site Number 840008", "city": "Avon", "state": "Indiana", "zip": "46123", "country": "United States", "geoPoint": {"lat": 39.76282, "lon": -86.39972}}, {"facility": "Investigational Site Number 840015", "city": "Avon", "state": "Indiana", "zip": "46123", "country": "United States", "geoPoint": {"lat": 39.76282, "lon": -86.39972}}, {"facility": "Investigational Site Number 840076", "city": "Avon", "state": "Indiana", "zip": "46123", "country": "United States", "geoPoint": {"lat": 39.76282, "lon": -86.39972}}, {"facility": "Investigational Site Number 840082", "city": "Evansville", "state": "Indiana", "zip": "47713", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Investigational Site Number 840031", "city": "Evansville", "state": "Indiana", "zip": "47714", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Investigational Site Number 840060", "city": "Evansville", "state": "Indiana", "zip": "47714", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Investigational Site Number 840048", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Investigational Site Number 840085", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Investigational Site Number 840012", "city": "Valparaiso", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.47309, "lon": -87.06114}}, {"facility": "Investigational Site Number 840025", "city": "Waterloo", "state": "Iowa", "zip": "50702", "country": "United States", "geoPoint": {"lat": 42.49276, "lon": -92.34296}}, {"facility": "Investigational Site Number 840022", "city": "Lexington", "state": "Kentucky", "zip": "40504", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Investigational Site Number 840007", "city": "Louisville", "state": "Kentucky", "zip": "40213", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Investigational Site Number 840081", "city": "New Orleans", "state": "Louisiana", "zip": "70112", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Investigational Site Number 840097", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "Investigational Site Number 840063", "city": "Rockville", "state": "Maryland", "zip": "20852", "country": "United States", "geoPoint": {"lat": 39.084, "lon": -77.15276}}, {"facility": "Investigational Site Number 840028", "city": "Bloomfield Hills", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.58364, "lon": -83.24549}}, {"facility": "Investigational Site Number 840071", "city": "Chesterfield", "state": "Michigan", "zip": "48047", "country": "United States", "geoPoint": {"lat": 42.66281, "lon": -82.84242}}, {"facility": "Investigational Site Number 840001", "city": "Dearborn", "state": "Michigan", "zip": "48124", "country": "United States", "geoPoint": {"lat": 42.32226, "lon": -83.17631}}, {"facility": "Investigational Site Number 840091", "city": "Kalamazoo", "state": "Michigan", "zip": "49048", "country": "United States", "geoPoint": {"lat": 42.29171, "lon": -85.58723}}, {"facility": "Investigational Site Number 840009", "city": "Minneapolis", "state": "Minnesota", "zip": "55416", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Investigational Site Number 840024", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "Investigational Site Number 840057", "city": "Butte", "state": "Montana", "zip": "59701", "country": "United States", "geoPoint": {"lat": 46.00382, "lon": -112.53474}}, {"facility": "Investigational Site Number 840042", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Investigational Site Number 840109", "city": "Henderson", "state": "Nevada", "zip": "89052", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Investigational Site Number 840052", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Investigational Site Number 840069", "city": "Nashua", "state": "New Hampshire", "zip": "03063", "country": "United States", "geoPoint": {"lat": 42.76537, "lon": -71.46757}}, {"facility": "Investigational Site Number 840123", "city": "Morganville", "state": "New Jersey", "zip": "07751", "country": "United States", "geoPoint": {"lat": 40.3765, "lon": -74.24431}}, {"facility": "Investigational Site Number 840011", "city": "Albuquerque", "state": "New Mexico", "zip": "87131", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Investigational Site Number 840030", "city": "New Hyde Park", "state": "New York", "zip": "11042", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "Investigational Site Number 840096", "city": "Syracuse", "state": "New York", "zip": "13214-2016", "country": "United States", "geoPoint": {"lat": 43.04812, "lon": -76.14742}}, {"facility": "Investigational Site Number 840039", "city": "Asheville", "state": "North Carolina", "zip": "28803", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Investigational Site Number 840021", "city": "Hickory", "state": "North Carolina", "zip": "28601", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"facility": "Investigational Site Number 840046", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Investigational Site Number 840072", "city": "Morganton", "state": "North Carolina", "zip": "28655", "country": "United States", "geoPoint": {"lat": 35.74541, "lon": -81.68482}}, {"facility": "Investigational Site Number 840110", "city": "Salisbury", "state": "North Carolina", "zip": "28144", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "Investigational Site Number 840095", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Investigational Site Number 840099", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Investigational Site Number 840004", "city": "Columbus", "state": "Ohio", "zip": "43213", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Investigational Site Number 840016", "city": "Maumee", "state": "Ohio", "zip": "43537", "country": "United States", "geoPoint": {"lat": 41.56283, "lon": -83.65382}}, {"facility": "Investigational Site Number 840103", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Investigational Site Number 840113", "city": "Portland", "state": "Oregon", "zip": "97201-3098", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Investigational Site Number 840036", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15473", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840043", "city": "Tipton", "state": "Pennsylvania", "zip": "16684", "country": "United States", "geoPoint": {"lat": 40.6359, "lon": -78.29585}}, {"facility": "Investigational Site Number 840058", "city": "Anderson", "state": "South Carolina", "zip": "29621", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"facility": "Investigational Site Number 840127", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Investigational Site Number 840049", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "Investigational Site Number 840114", "city": "Rapid City", "state": "South Dakota", "zip": "57701", "country": "United States", "geoPoint": {"lat": 44.08054, "lon": -103.23101}}, {"facility": "Investigational Site Number 840112", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Investigational Site Number 840094", "city": "Knoxville", "state": "Tennessee", "zip": "37912", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Investigational Site Number 840051", "city": "Austin", "state": "Texas", "zip": "78758", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Investigational Site Number 840066", "city": "Corpus Christi", "state": "Texas", "zip": "78404", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Investigational Site Number 840111", "city": "Dallas", "state": "Texas", "zip": "75208", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840020", "city": "Dallas", "state": "Texas", "zip": "75216", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840064", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840003", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840088", "city": "Edinburg", "state": "Texas", "zip": "78539", "country": "United States", "geoPoint": {"lat": 26.30174, "lon": -98.16334}}, {"facility": "Investigational Site Number 840118", "city": "Fort Worth", "state": "Texas", "zip": "76132", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number 840055", "city": "Houston", "state": "Texas", "zip": "77004", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Investigational Site Number 840087", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Investigational Site Number 840079", "city": "Hurst", "state": "Texas", "zip": "76054", "country": "United States", "geoPoint": {"lat": 32.82346, "lon": -97.17057}}, {"facility": "Investigational Site Number 840073", "city": "N Richland Hill", "state": "Texas", "zip": "76180", "country": "United States", "geoPoint": {"lat": 32.8343, "lon": -97.2289}}, {"facility": "Investigational Site Number 840019", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Investigational Site Number 840037", "city": "Draper", "state": "Utah", "zip": "84020", "country": "United States", "geoPoint": {"lat": 40.52467, "lon": -111.86382}}, {"facility": "Investigational Site Number 840093", "city": "Ogden", "state": "Utah", "zip": "84405", "country": "United States", "geoPoint": {"lat": 41.223, "lon": -111.97383}}, {"facility": "Investigational Site Number 840061", "city": "Salt Lake City", "state": "Utah", "zip": "84102", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Investigational Site Number 840041", "city": "Salt Lake City", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Investigational Site Number 840040", "city": "Chesapeake", "state": "Virginia", "zip": "23321", "country": "United States", "geoPoint": {"lat": 36.81904, "lon": -76.27494}}, {"facility": "Investigational Site Number 840045", "city": "Norfolk", "state": "Virginia", "zip": "23510", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Investigational Site Number 840092", "city": "Norfolk", "state": "Virginia", "zip": "23510", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Investigational Site Number 840125", "city": "Richmond", "state": "Virginia", "zip": "23219", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Investigational Site Number 840115", "city": "Salem", "state": "Virginia", "zip": "24153", "country": "United States", "geoPoint": {"lat": 37.29347, "lon": -80.05476}}, {"facility": "Investigational Site Number 840010", "city": "Weber City", "state": "Virginia", "zip": "24290", "country": "United States", "geoPoint": {"lat": 37.75514, "lon": -78.28389}}, {"facility": "Investigational Site Number 840077", "city": "Federal Way", "state": "Washington", "zip": "98003", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"facility": "Investigational Site Number 840102", "city": "Renton", "state": "Washington", "zip": "98055", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}, {"facility": "Investigational Site Number 840033", "city": "Milwaukee", "state": "Wisconsin", "zip": "53209-0996", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Investigational Site Number 036005", "city": "Box Hill", "zip": "3128", "country": "Australia", "geoPoint": {"lat": -37.81887, "lon": 145.12545}}, {"facility": "Investigational Site Number 036001", "city": "Camperdown", "zip": "2050", "country": "Australia", "geoPoint": {"lat": -33.88965, "lon": 151.17642}}, {"facility": "Investigational Site Number 036006", "city": "Kippa Ring", "zip": "4021", "country": "Australia", "geoPoint": {"lat": -27.22586, "lon": 153.0835}}, {"facility": "Investigational Site Number 036007", "city": "Logan Central", "zip": "4114", "country": "Australia", "geoPoint": {"lat": -27.64385, "lon": 153.10725}}, {"facility": "Investigational Site Number 056005", "city": "Brussels", "zip": "1070", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Investigational Site Number 056006", "city": "Brussel", "zip": "1090", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Investigational Site Number 056001", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Investigational Site Number 124004", "city": "Kelowna", "zip": "V1Y 1Z9", "country": "Canada", "geoPoint": {"lat": 49.88307, "lon": -119.48568}}, {"facility": "Investigational Site Number 124001", "city": "Toronto", "zip": "M4G 3E8", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124002", "city": "Vancouver", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number 152008", "city": "Osorno", "zip": "5311092", "country": "Chile", "geoPoint": {"lat": -40.57395, "lon": -73.13348}}, {"facility": "Investigational Site Number 152015", "city": "Puerto Varas", "country": "Chile", "geoPoint": {"lat": -41.31946, "lon": -72.98538}}, {"facility": "Investigational Site Number 152004", "city": "Santiago", "zip": "7500010", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152006", "city": "Santiago", "zip": "7500010", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152001", "city": "Santiago", "zip": "7591047", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152002", "city": "Santiago", "zip": "7980378", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152012", "city": "Santiago", "zip": "8053095", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152009", "city": "Santiago", "zip": "8330008", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152011", "city": "Talagante", "country": "Chile", "geoPoint": {"lat": -33.66386, "lon": -70.92734}}, {"facility": "Investigational Site Number 152014", "city": "Temuco", "zip": "4781156", "country": "Chile", "geoPoint": {"lat": -38.73965, "lon": -72.59842}}, {"facility": "Investigational Site Number 152003", "city": "Temuco", "zip": "4813299", "country": "Chile", "geoPoint": {"lat": -38.73965, "lon": -72.59842}}, {"facility": "Investigational Site Number 203004", "city": "Beroun", "zip": "26601", "country": "Czech Republic", "geoPoint": {"lat": 49.96382, "lon": 14.072}}, {"facility": "Investigational Site Number 203008", "city": "Ceske Budejovice", "zip": "370 01", "country": "Czech Republic", "geoPoint": {"lat": 48.97447, "lon": 14.47434}}, {"facility": "Investigational Site Number 203014", "city": "Horovice", "zip": "26801", "country": "Czech Republic", "geoPoint": {"lat": 49.83597, "lon": 13.90268}}, {"facility": "Investigational Site Number 203012", "city": "Koprivnice", "zip": "742 21", "country": "Czech Republic", "geoPoint": {"lat": 49.59947, "lon": 18.1448}}, {"facility": "Investigational Site Number 203001", "city": "Pardubice", "zip": "53002", "country": "Czech Republic", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"facility": "Investigational Site Number 203005", "city": "Plzen", "zip": "32600", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Investigational Site Number 203003", "city": "Praha 10", "zip": "100 00", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Investigational Site Number 203009", "city": "Praha 2", "zip": "12808", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Investigational Site Number 203007", "city": "Praha 5", "zip": "15000", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Investigational Site Number 203013", "city": "Praha 9 - Klanovice", "zip": "19014", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Investigational Site Number 203006", "city": "Trutnov", "zip": "54101", "country": "Czech Republic", "geoPoint": {"lat": 50.56101, "lon": 15.9127}}, {"facility": "Investigational Site Number 203016", "city": "Ujezd U Brna", "country": "Czech Republic"}, {"facility": "Investigational Site Number 203015", "city": "Vsetin", "zip": "75501", "country": "Czech Republic", "geoPoint": {"lat": 49.33871, "lon": 17.99619}}, {"facility": "Investigational Site Number 208003", "city": "Aarhus C", "zip": "8000", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"facility": "Investigational Site Number 208009", "city": "Horsens", "zip": "8700", "country": "Denmark", "geoPoint": {"lat": 55.86066, "lon": 9.85034}}, {"facility": "Investigational Site Number 208002", "city": "Kolding", "zip": "6000", "country": "Denmark", "geoPoint": {"lat": 55.4904, "lon": 9.47216}}, {"facility": "Investigational Site Number 208001", "city": "K\u00f8benhavn Nv", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Investigational Site Number 208005", "city": "K\u00f8benhavn S", "zip": "2300", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Investigational Site Number 208004", "city": "Viborg", "zip": "8800", "country": "Denmark", "geoPoint": {"lat": 56.45319, "lon": 9.40201}}, {"facility": "Investigational Site Number 233004", "city": "Paide", "zip": "72713", "country": "Estonia", "geoPoint": {"lat": 58.88556, "lon": 25.55722}}, {"facility": "Investigational Site Number 233002", "city": "P\u00e4rnu", "zip": "80018", "country": "Estonia", "geoPoint": {"lat": 58.38588, "lon": 24.49711}}, {"facility": "Investigational Site Number 233003", "city": "Tallinn", "zip": "13415", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Investigational Site Number 233001", "city": "Viljandimaa", "zip": "71024", "country": "Estonia"}, {"facility": "Investigational Site Number 250006", "city": "Corbeil Essonnes", "zip": "91109", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "Investigational Site Number 250002", "city": "La Rochelle Cedex", "zip": "17019", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "Investigational Site Number 250003", "city": "Pierre Benite", "zip": "69310", "country": "France", "geoPoint": {"lat": 45.7009, "lon": 4.82511}}, {"facility": "Investigational Site Number 250001", "city": "Venissieux", "zip": "69200", "country": "France", "geoPoint": {"lat": 45.70254, "lon": 4.87147}}, {"facility": "Investigational Site Number 276005", "city": "Berlin", "zip": "10115", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigational Site Number 276003", "city": "Berlin", "zip": "13125", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigational Site Number 276004", "city": "Dortmund", "zip": "44137", "country": "Germany", "geoPoint": {"lat": 51.51494, "lon": 7.466}}, {"facility": "Investigational Site Number 276007", "city": "Dresden", "zip": "01069", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Investigational Site Number 276001", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Investigational Site Number 276006", "city": "Hamburg", "zip": "20253", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Investigational Site Number 276002", "city": "Neum\u00fcnster", "zip": "24534", "country": "Germany", "geoPoint": {"lat": 54.07477, "lon": 9.98195}}, {"facility": "Investigational Site Number 348003", "city": "Balatonf\u00fcred", "zip": "8230", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Investigational Site Number 348007", "city": "Budapest", "zip": "1036", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Investigational Site Number 348006", "city": "Budapest", "zip": "1096", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Investigational Site Number 348002", "city": "Budapest", "zip": "1138", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Investigational Site Number 348011", "city": "Kom\u00e1rom", "zip": "2900", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Investigational Site Number 348008", "city": "Nagykanizsa", "zip": "8800", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "Investigational Site Number 348004", "city": "Szeged", "zip": "6720", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Investigational Site Number 348010", "city": "Szekesfehervar", "zip": "8000", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Investigational Site Number 348012", "city": "S\u00e1toralja\u00fajhely", "zip": "3980", "country": "Hungary", "geoPoint": {"lat": 48.39492, "lon": 21.65871}}, {"facility": "Investigational Site Number 348001", "city": "Zalaegerszeg", "zip": "8900", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"facility": "Investigational Site Number 380002", "city": "Bologna", "zip": "40138", "country": "Italy", "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "Investigational Site Number 380006", "city": "Catanzaro", "zip": "88100", "country": "Italy", "geoPoint": {"lat": 38.88247, "lon": 16.60086}}, {"facility": "Investigational Site Number 380001", "city": "Milano", "zip": "20132", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Investigational Site Number 380003", "city": "Napoli", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Investigational Site Number 380005", "city": "Roma", "zip": "00133", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Investigational Site Number 428002", "city": "Riga", "zip": "LV-1011", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Investigational Site Number 428003", "city": "Riga", "zip": "LV-1011", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Investigational Site Number 428004", "city": "Riga", "zip": "LV-1050", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Investigational Site Number 428001", "city": "Sigulda", "zip": "LV-2150", "country": "Latvia", "geoPoint": {"lat": 57.15194, "lon": 24.86472}}, {"facility": "Investigational Site Number 440003", "city": "Jonava", "zip": "LT-55201", "country": "Lithuania", "geoPoint": {"lat": 55.08333, "lon": 24.28333}}, {"facility": "Investigational Site Number 440002", "city": "Kaunas", "zip": "LT-49456", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Investigational Site Number 440007", "city": "Kaunas", "zip": "LT-50009", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Investigational Site Number 440004", "city": "Kedainiai", "zip": "LT-57164", "country": "Lithuania", "geoPoint": {"lat": 55.28782, "lon": 23.97276}}, {"facility": "Investigational Site Number 440006", "city": "Panevezys", "zip": "LT-37355", "country": "Lithuania", "geoPoint": {"lat": 55.73333, "lon": 24.35}}, {"facility": "Investigational Site Number 440005", "city": "Utena", "zip": "LT-28151", "country": "Lithuania", "geoPoint": {"lat": 55.49765, "lon": 25.59918}}, {"facility": "Investigational Site Number 440001", "city": "Vilnius", "zip": "LT-10323", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Investigational Site Number 484005", "city": "Aguascalientes", "zip": "20230", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Investigational Site Number 484001", "city": "Cuernavaca", "zip": "62250", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "Investigational Site Number 484002", "city": "Guadalajara", "zip": "44130", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484004", "city": "Guadalajara", "zip": "44210", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484009", "city": "Guadalajara", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484007", "city": "Monterrey", "zip": "64020", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484006", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484010", "city": "Zapopan", "zip": "45116", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Investigational Site Number 616002", "city": "Bialystok", "zip": "15-435", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Investigational Site Number 616005", "city": "Krakow", "zip": "31-261", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616006", "city": "Krakow", "zip": "31-548", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616007", "city": "Lodz", "zip": "94-074", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616004", "city": "Szczecin", "zip": "70-506", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Investigational Site Number 616003", "city": "Warszawa", "zip": "01-518", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigational Site Number 616001", "city": "Warszawa", "zip": "02-507", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigational Site Number 616008", "city": "Zory", "zip": "44-240", "country": "Poland", "geoPoint": {"lat": 50.04523, "lon": 18.70062}}, {"facility": "Investigational Site Number 642008", "city": "Bucharest", "zip": "010825", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigational Site Number 642007", "city": "Bucuresti", "zip": "020475", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Investigational Site Number 642009", "city": "Cluj Napoca", "zip": "400006", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642006", "city": "Hunedoara", "zip": "331057", "country": "Romania", "geoPoint": {"lat": 45.75, "lon": 22.9}}, {"facility": "Investigational Site Number 642005", "city": "Iasi", "zip": "700547", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Investigational Site Number 642002", "city": "Oradea", "zip": "410169", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"facility": "Investigational Site Number 642001", "city": "Targu Mures", "zip": "540142", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Investigational Site Number 642004", "city": "Timisoara", "zip": "300133", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 642003", "city": "Timisoara", "zip": "300456", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 643006", "city": "Moscow", "zip": "119991", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643008", "city": "Penza", "zip": "440026", "country": "Russian Federation", "geoPoint": {"lat": 53.20066, "lon": 45.00464}}, {"facility": "Investigational Site Number 643012", "city": "Petrozavodsk", "zip": "185019", "country": "Russian Federation", "geoPoint": {"lat": 61.78491, "lon": 34.34691}}, {"facility": "Investigational Site Number 643001", "city": "Saint-Petersburg", "zip": "190013", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643014", "city": "Samara", "zip": "443067", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "Investigational Site Number 643009", "city": "Saratov", "zip": "410026", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Investigational Site Number 643011", "city": "Saratov", "zip": "410053", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Investigational Site Number 643005", "city": "St-Petersburg", "zip": "190068", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643007", "city": "St-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643002", "city": "St-Petersburg", "zip": "195257", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643003", "city": "St. Petersburg", "zip": "194358", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643016", "city": "Tomsk", "zip": "634050", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Investigational Site Number 643004", "city": "Voronezh", "zip": "394018", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Investigational Site Number 710002", "city": "Cap Town", "zip": "7530", "country": "South Africa"}, {"facility": "Investigational Site Number 710003", "city": "Cape Town", "zip": "7500", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710005", "city": "Meyerspark", "zip": "0184", "country": "South Africa", "geoPoint": {"lat": -25.74111, "lon": 28.32162}}, {"facility": "Investigational Site Number 710007", "city": "Port Elizabeth", "country": "South Africa", "geoPoint": {"lat": -33.91799, "lon": 25.57007}}, {"facility": "Investigational Site Number 710004", "city": "Pretoria", "zip": "0122", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Investigational Site Number 710001", "city": "Somerset West", "zip": "7130", "country": "South Africa", "geoPoint": {"lat": -34.08401, "lon": 18.82113}}, {"facility": "Investigational Site Number 710006", "city": "Soweto", "zip": "4309", "country": "South Africa", "geoPoint": {"lat": -26.26781, "lon": 27.85849}}, {"facility": "Investigational Site Number 724012", "city": "Barcelona", "zip": "08003", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724009", "city": "Granada", "zip": "18012", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "Investigational Site Number 724004", "city": "Hostalets De Baleny\u00e0", "zip": "08550", "country": "Spain"}, {"facility": "Investigational Site Number 724011", "city": "La Coru\u00f1a", "zip": "15006", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Investigational Site Number 724007", "city": "Lugo", "zip": "27004", "country": "Spain", "geoPoint": {"lat": 43.00992, "lon": -7.55602}}, {"facility": "Investigational Site Number 724008", "city": "Madrid", "zip": "28034", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Investigational Site Number 724005", "city": "Madrid", "zip": "28046", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Investigational Site Number 724013", "city": "Palma De Mallorca", "zip": "07010", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "Investigational Site Number 724001", "city": "Quart De Poblet", "zip": "46930", "country": "Spain", "geoPoint": {"lat": 39.48139, "lon": -0.43937}}, {"facility": "Investigational Site Number 724006", "city": "Sant Joan Desp\u00ed", "zip": "08970", "country": "Spain", "geoPoint": {"lat": 41.36718, "lon": 2.0574}}, {"facility": "Investigational Site Number 724003", "city": "Sevilla", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Investigational Site Number 752001", "city": "Ljungby", "zip": "341 82", "country": "Sweden", "geoPoint": {"lat": 56.83324, "lon": 13.94082}}, {"facility": "Investigational Site Number 752003", "city": "Malm\u00f6", "zip": "211 52", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "Investigational Site Number 752004", "city": "R\u00e4ttvik", "zip": "79530", "country": "Sweden", "geoPoint": {"lat": 60.88632, "lon": 15.11787}}, {"facility": "Investigational Site Number 752005", "city": "Stockholm", "zip": "11526", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Investigational Site Number 752002", "city": "V\u00e4llingby", "zip": "16268", "country": "Sweden", "geoPoint": {"lat": 59.36441, "lon": 17.87407}}, {"facility": "Investigational Site Number 804002", "city": "Chernivtsi", "zip": "58022", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Investigational Site Number 804009", "city": "Ivano-Frankovsk", "zip": "76008", "country": "Ukraine"}, {"facility": "Investigational Site Number 804010", "city": "Kyiv", "zip": "03049", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804007", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804006", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804012", "city": "Lviv", "zip": "79010", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Investigational Site Number 804011", "city": "Vinnytsya", "zip": "21001", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Investigational Site Number 804008", "city": "Vinnytsya", "zip": "21010", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Investigational Site Number 826001", "city": "Coventry", "zip": "CV2 2DX", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Investigational Site Number 826002", "city": "Dundee", "zip": "DD1 9SI", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "Investigational Site Number 826006", "city": "Guildford", "zip": "GU2 7XX", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}, {"facility": "Investigational Site Number 826007", "city": "Leicester", "zip": "LE5 4PW", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Investigational Site Number 826003", "city": "Norwich", "zip": "NR1 3SR", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}]}, "referencesModule": {"references": [{"pmid": "27527848", "type": "RESULT", "citation": "Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15. Erratum In: Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06c."}, {"pmid": "35101326", "type": "DERIVED", "citation": "Shao H, Kianmehr H, Guo J, Li P, Fonseca V, Shi L. Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. J Diabetes Complications. 2022 Mar;36(3):108132. doi: 10.1016/j.jdiacomp.2022.108132. Epub 2022 Jan 25."}, {"pmid": "31124299", "type": "DERIVED", "citation": "Davies MJ, Russell-Jones D, Barber TM, Lavalle-Gonzalez FJ, Galstyan GR, Zhu D, Baxter M, Dessapt-Baradez C, McCrimmon RJ. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diabetes Obes Metab. 2019 Aug;21(8):1967-1972. doi: 10.1111/dom.13791. Epub 2019 Jun 18."}, {"pmid": "31114694", "type": "DERIVED", "citation": "Dailey G, Bajaj HS, Dex T, Groleau M, Stager W, Vinik A. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000581. doi: 10.1136/bmjdrc-2018-000581. eCollection 2019."}, {"pmid": "30550345", "type": "DERIVED", "citation": "Schmider W, Belder R, Lee M, Niemoeller E, Souhami E, Frias JP. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. Curr Med Res Opin. 2019 Jun;35(6):1081-1089. doi: 10.1080/03007995.2018.1558852. Epub 2019 Jan 11."}, {"pmid": "29974618", "type": "DERIVED", "citation": "Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13."}, {"pmid": "29923298", "type": "DERIVED", "citation": "Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018 Nov;20(11):2690-2694. doi: 10.1111/dom.13444. Epub 2018 Aug 21."}, {"pmid": "28432746", "type": "DERIVED", "citation": "Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. Diabetes Obes Metab. 2017 Dec;19(12):1798-1804. doi: 10.1111/dom.12980. Epub 2017 Jul 7."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "After 2 weeks screening period, 1479 participants underwent 4-week run-in period. 309 participants were run-in failures. A total of 1170 participants were randomized in 2:2:1 to insulin glargine/lixisenatide, insulin glargine and lixisenatide arms respectively in open-label treatment period.", "recruitmentDetails": "The study was conducted at 240 centers in 23 countries. A total of 2457 participants were screened between February 12, 2014 and September 16, 2014. 978 participants were not eligible for run-in mainly due to glycosylated hemoglobin (HbA1c) value at screening visit being out of the protocol defined range.", "groups": [{"id": "FG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)", "description": "FRC injected subcutaneously once daily (QD) for 30 weeks. Dose individually adjusted."}, {"id": "FG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "FG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "469"}, {"groupId": "FG001", "numSubjects": "467"}, {"groupId": "FG002", "numSubjects": "234"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "469"}, {"groupId": "FG001", "numSubjects": "467"}, {"groupId": "FG002", "numSubjects": "233"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "440"}, {"groupId": "FG001", "numSubjects": "440"}, {"groupId": "FG002", "numSubjects": "205"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Randomized but not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "21"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Poor compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Other than specified", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "BG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "BG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "469"}, {"groupId": "BG001", "value": "467"}, {"groupId": "BG002", "value": "234"}, {"groupId": "BG003", "value": "1170"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.2", "spread": "9.5"}, {"groupId": "BG001", "value": "58.3", "spread": "9.4"}, {"groupId": "BG002", "value": "58.7", "spread": "8.7"}, {"groupId": "BG003", "value": "58.4", "spread": "9.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "247"}, {"groupId": "BG001", "value": "230"}, {"groupId": "BG002", "value": "101"}, {"groupId": "BG003", "value": "578"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "222"}, {"groupId": "BG001", "value": "237"}, {"groupId": "BG002", "value": "133"}, {"groupId": "BG003", "value": "592"}]}]}]}, {"title": "Race", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "417"}, {"groupId": "BG001", "value": "421"}, {"groupId": "BG002", "value": "216"}, {"groupId": "BG003", "value": "1054"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "78"}]}]}, {"title": "Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "20"}]}]}]}, {"title": "Ethnicity", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "223"}]}]}, {"title": "Not Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "384"}, {"groupId": "BG001", "value": "380"}, {"groupId": "BG002", "value": "183"}, {"groupId": "BG003", "value": "947"}]}]}]}, {"title": "Second Oral Anti-diabetic Drug (OAD) Use", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "274"}, {"groupId": "BG001", "value": "270"}, {"groupId": "BG002", "value": "133"}, {"groupId": "BG003", "value": "677"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "195"}, {"groupId": "BG001", "value": "197"}, {"groupId": "BG002", "value": "101"}, {"groupId": "BG003", "value": "493"}]}]}]}, {"title": "Second OAD Use at Screening by Class", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Sulfonylurea", "categories": [{"measurements": [{"groupId": "BG000", "value": "259"}, {"groupId": "BG001", "value": "249"}, {"groupId": "BG002", "value": "123"}, {"groupId": "BG003", "value": "631"}]}]}, {"title": "Glinide", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Sodium-glucose co-transporter-2 inhibitor", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "4"}]}]}, {"title": "Dipeptidyl peptidase-4 inhibitor", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "28"}]}]}, {"title": "None", "categories": [{"measurements": [{"groupId": "BG000", "value": "193"}, {"groupId": "BG001", "value": "195"}, {"groupId": "BG002", "value": "101"}, {"groupId": "BG003", "value": "489"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.64", "spread": "4.4"}, {"groupId": "BG001", "value": "31.66", "spread": "4.51"}, {"groupId": "BG002", "value": "31.99", "spread": "4.39"}, {"groupId": "BG003", "value": "31.72", "spread": "4.44"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.89", "spread": "5.51"}, {"groupId": "BG001", "value": "8.66", "spread": "5.59"}, {"groupId": "BG002", "value": "8.89", "spread": "6.26"}, {"groupId": "BG003", "value": "8.80", "spread": "5.69"}]}]}]}, {"title": "Daily Dose of Metformin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2246.1", "spread": "456.8"}, {"groupId": "BG001", "value": "2244.7", "spread": "444.7"}, {"groupId": "BG002", "value": "2267.3", "spread": "427.4"}, {"groupId": "BG003", "value": "2249.8", "spread": "445.9"}]}]}]}, {"title": "HbA1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of HbA1c", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.08", "spread": "0.71"}, {"groupId": "BG001", "value": "8.08", "spread": "0.69"}, {"groupId": "BG002", "value": "8.13", "spread": "0.72"}, {"groupId": "BG003", "value": "8.09", "spread": "0.70"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.87", "spread": "2.35"}, {"groupId": "BG001", "value": "9.75", "spread": "2.32"}, {"groupId": "BG002", "value": "9.75", "spread": "2.19"}, {"groupId": "BG003", "value": "9.80", "spread": "2.31"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in HbA1c From Baseline to Week 30", "description": "Primary outcome was to test superiority of FRC versus Lixisenatide and non-inferiority versus Insulin glargine.\n\nChange in HbA1c was calculated by subtracting baseline value from Week 30 value.", "populationDescription": "Modified intent-to-treat (mITT) population: all randomized participants who had both baseline and at least one post-baseline efficacy assessment. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "467"}, {"groupId": "OG001", "value": "464"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.63", "spread": "0.038"}, {"groupId": "OG001", "value": "-1.34", "spread": "0.039"}, {"groupId": "OG002", "value": "-0.85", "spread": "0.052"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Analysis was performed using Mixed-effect model with repeated measures (MMRM) with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline HbA1c value-by-visit interaction as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u22640.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least Square (LS) Mean Difference", "paramValue": "-0.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.898", "ciUpperLimit": "-0.665", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Lixisenatide"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline HbA1c value-by-visit interaction as a covariate.", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Predefined non-inferiority margin of 0.3%.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.384", "ciUpperLimit": "-0.194", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin glargine"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Test of superiority was also performed as a secondary endpoint according to hierarchical testing procedure. Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline HbA1c value-by-visit interaction, as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.384", "ciUpperLimit": "-0.194", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin glargine"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c <7.0% or \u22646.5% at Week 30", "description": "Participants without Week 30 value for HbA1c were counted as non-responders.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "466"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"title": "HbA1c <7.0%", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.7"}, {"groupId": "OG001", "value": "59.4"}, {"groupId": "OG002", "value": "33"}]}]}, {"title": "HbA1c \u22646.5%", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.8"}, {"groupId": "OG001", "value": "39.5"}, {"groupId": "OG002", "value": "19.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "HbA1c \\<7.0%: Insulin Glargine/Lixisenatide FRC vs Lixisenatide.\n\nAnalysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8.0%, \u22658.0%) and randomization strata of second OAD use at screening. This analysis was out of testing order.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u22640.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "40.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "33.63", "ciUpperLimit": "47.59", "estimateComment": "HbA1c \\<7.0%: Insulin Glargine/Lixisenatide FRC vs Lixisenatide."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "HbA1c \u22646.5%: Insulin Glargine/Lixisenatide FRC vs Lixisenatide.\n\nAnalysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8.0%, \u22658.0%) and randomization strata of second OAD use at screening. This analysis was out of testing order.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "36.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "29.81", "ciUpperLimit": "42.95", "estimateComment": "HbA1c \u22646.5%: Insulin Glargine/Lixisenatide FRC vs Lixisenatide."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HbA1c \\<7.0%: Insulin Glargine/Lixisenatide FRC vs Insulin glargine.\n\nAnalysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8.0%, \u22658.0%) and randomization strata of second OAD use at screening. This analysis was out of testing order.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "14.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.37", "ciUpperLimit": "20.25", "estimateComment": "HbA1c \\<7.0%: Insulin Glargine/Lixisenatide FRC vs Insulin glargine."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HbA1c \u22646.5%: Insulin Glargine/Lixisenatide FRC vs Insulin glargine.\n\nAnalysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8.0%, \u22658.0%) and randomization strata of second OAD use at screening. This analysis was out of testing order.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "16.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.13", "ciUpperLimit": "22.58", "estimateComment": "HbA1c \u22646.5%: Insulin Glargine/Lixisenatide FRC vs Insulin glargine."}]}, {"type": "SECONDARY", "title": "Change in Plasma Glucose Excursion From Baseline to Week 30", "description": "Plasma glucose excursion = 2-hour postprandial plasma glucose (PPG) value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 30 value. Missing data was imputed using last observation carried forward (LOCF).", "populationDescription": "mITT population. Here, number of participants analyzed = participants with baseline and at least one post-baseline plasma glucose excursion assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "428"}, {"groupId": "OG001", "value": "425"}, {"groupId": "OG002", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.31", "spread": "0.154"}, {"groupId": "OG001", "value": "-0.18", "spread": "0.157"}, {"groupId": "OG002", "value": "-3.23", "spread": "0.216"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using analysis of covariance (ANCOVA) model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0,\u22658.0%), randomization strata of second OAD use at screening \\& country as fixed effects \\& baseline plasma glucose excursion value as a covariate. Hierarchical testing procedure was used to control type I error and handle multiple secondary endpoint analyses. Testing was then performed sequentially per pre-specified order.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u22640.05. The hierarchical testing continued only when primary hypotheses (superiority: FRC to lixisenatide; non-inferiority: FRC to insulin glargine for HbA1c) was statistically significant.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-2.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.498", "ciUpperLimit": "-1.77", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.185", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin glargine."}]}, {"type": "SECONDARY", "title": "Change in Body Weight From Baseline to Week 30", "description": "Change in body weight was calculated by subtracting baseline value from Week 30 value.", "populationDescription": "mITT population. Here, number of participants analyzed = participants with baseline and at least one post-baseline body weight assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "467"}, {"groupId": "OG001", "value": "465"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.29", "spread": "0.182"}, {"groupId": "OG001", "value": "1.11", "spread": "0.183"}, {"groupId": "OG002", "value": "-2.3", "spread": "0.256"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline body weight value-by-visit interaction as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.891", "ciUpperLimit": "-0.91", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.25", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin glargine"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 30", "description": "Change in FPG was calculated by subtracting baseline value from Week 30 value.", "populationDescription": "mITT population. Here, number of participants analysed = participants with baseline and at least one post-baseline FPG assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "465"}, {"groupId": "OG001", "value": "465"}, {"groupId": "OG002", "value": "232"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.46", "spread": "0.09"}, {"groupId": "OG001", "value": "-3.27", "spread": "0.091"}, {"groupId": "OG002", "value": "-1.5", "spread": "0.124"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline FPG value-by-visit interaction as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-1.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.246", "ciUpperLimit": "-1.682", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.144", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Lixisenatide"}]}, {"type": "SECONDARY", "title": "Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30", "description": "Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.", "populationDescription": "mITT population. Here,number of participants analyzed = participants with baseline and at least one post baseline 7-point SMPG assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "421"}, {"groupId": "OG001", "value": "411"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.35", "spread": "0.081"}, {"groupId": "OG001", "value": "-2.66", "spread": "0.084"}, {"groupId": "OG002", "value": "-1.95", "spread": "0.111"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline 7-point SMPG value-by-visit interaction as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.645", "ciUpperLimit": "-1.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.124", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Lixisenatide"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects and baseline 7-point SMPG value-by-visit interaction, as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.892", "ciUpperLimit": "-0.495", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.101", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin Glargine"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30", "populationDescription": "mITT population. Participants without any HbA1c and/or body weight value at Week 30 were counted as non-responders.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "466"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43.2"}, {"groupId": "OG001", "value": "25.1"}, {"groupId": "OG002", "value": "27.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8%, \u22658%) and randomization strata of second OAD use at screening.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "18.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.15", "ciUpperLimit": "24.01", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin glargine"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] \u2264 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period", "description": "Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u226470 mg/dL (3.9 mmol/L).", "populationDescription": "mITT population. Participants without any HbA1c and/or body weight value at Week 30 were counted as non-responders.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "466"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.8"}, {"groupId": "OG001", "value": "18.9"}, {"groupId": "OG002", "value": "26.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using Cochran-Mantel-Haenszel method stratified on randomization strata of Week -1 HbA1c (\\<8.0%, \u22658.0%) and randomization strata of second OAD use at screening.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "< 0.0001", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference in percentage", "paramValue": "12.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.5", "ciUpperLimit": "18.45", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin Glargine"}]}, {"type": "SECONDARY", "title": "Average Daily Insulin Glargine Dose at Week 30", "description": "The analysis included scheduled measurements obtained up to the date of last injection of the IMP, including those obtained after introduction of rescue therapy.", "populationDescription": "mITT population. Here, number of participants analyzed = participants with insulin glargine dose assessment during study period. Data of this endpoint was planned to be analyzed for Insulin Glargine/Lixisenatide FRC and Insulin glargine arms only, not for lixisenatide arm.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units (U)", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "467"}, {"groupId": "OG001", "value": "463"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "39.77", "spread": "0.699"}, {"groupId": "OG001", "value": "40.46", "spread": "0.701"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Testing according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant). Analysis was performed using MMRM model with treatment groups, randomization strata of Week -1 HbA1c (\\<8.0, \u22658.0%), randomization strata of second OAD use at screening, visits, treatment-by-visit interaction, and country as fixed effects.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4857", "pValueComment": "Threshold for significance \u2264 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.632", "ciUpperLimit": "1.252", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.99", "estimateComment": "Insulin Glargine/Lixisenatide FRC vs Insulin Glargine"}]}, {"type": "SECONDARY", "title": "Change in 2-Hour Postprandial Plasma Glucose (PPG) From Baseline to Week 30", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 30 value. Missing data was imputed using LOCF.", "populationDescription": "mITT population. Here, number of participants analyzed = participants with baseline and at least one post-baseline 2-hour PPG assessment during study period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "430"}, {"groupId": "OG001", "value": "430"}, {"groupId": "OG002", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.68", "spread": "0.176"}, {"groupId": "OG001", "value": "-3.31", "spread": "0.178"}, {"groupId": "OG002", "value": "-4.58", "spread": "0.245"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Reaching HbA1c <7.0% at Week 30 With No Documented Symptomatic Hypoglycemia (PG \u2264 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period", "description": "Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u226470 mg/dL (3.9 mmol/L). The analysis included all HbA1c measurements at Week 30, including those obtained after the IMP discontinuation or the introduction of rescue medication.", "populationDescription": "mITT population. Participants without Week 30 value for HbA1c were counted as non-responders.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "466"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.6"}, {"groupId": "OG001", "value": "44.4"}, {"groupId": "OG002", "value": "30.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period", "description": "Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) was performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8%.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 30", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "466"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.6"}, {"groupId": "OG001", "value": "3.4"}, {"groupId": "OG002", "value": "12.4"}]}]}]}, {"type": "SECONDARY", "title": "Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year", "description": "Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u2264 70 mg/dL (3.9 mmol/L).", "populationDescription": "Analysis was performed on safety population defined as all randomized participants who received at least one dose of IMP regardless of the amount of treatment administered.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events per subject-year", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "469"}, {"groupId": "OG001", "value": "467"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.44"}, {"groupId": "OG001", "value": "1.22"}, {"groupId": "OG002", "value": "0.34"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Documented Symptomatic Hypoglycemia", "description": "Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \u2264 70 mg/dL (3.9 mmol/L).", "populationDescription": "Safety population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "469"}, {"groupId": "OG001", "value": "467"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.6"}, {"groupId": "OG001", "value": "23.6"}, {"groupId": "OG002", "value": "6.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Severe Symptomatic Hypoglycemia", "description": "Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not have been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk of injury to themselves or others.", "populationDescription": "Safety population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)", "groups": [{"id": "OG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted."}, {"id": "OG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "469"}, {"groupId": "OG001", "value": "467"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0.2"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Day 213) regardless of seriousness or relationship to investigational product.", "description": "Reported AEs are treatment-emergent that is AEs that developed/worsened during 'on-treatment period' (time from first injection of open-label IMP up to 3 days after the last injection of IMP regardless of the introduction of rescue therapy). Analysis was done on safety population.", "eventGroups": [{"id": "EG000", "title": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "description": "FRC injected subcutaneously QD for 30 weeks. Dose individually adjusted (median exposure: 211 days).", "seriousNumAffected": 18, "seriousNumAtRisk": 469, "otherNumAffected": 138, "otherNumAtRisk": 469}, {"id": "EG001", "title": "Insulin Glargine", "description": "Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted (median exposure: 211 days).", "seriousNumAffected": 19, "seriousNumAtRisk": 467, "otherNumAffected": 85, "otherNumAtRisk": 467}, {"id": "EG002", "title": "Lixisenatide", "description": "Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose) median exposure: 211 days).", "seriousNumAffected": 9, "seriousNumAtRisk": 233, "otherNumAffected": 98, "otherNumAtRisk": 233}], "seriousEvents": [{"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Febrile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Meningitis staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Lung cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Squamous cell carcinoma of skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Metastases to liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Prostate cancer recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Squamous cell carcinoma of the oral cavity", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Thyroid adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Pancytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Lacunar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Bladder prolapse", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Calculus urinary", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Acquired phimosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Cervical dysplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Electrocardiogram ST-T segment abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Lipase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Comminuted fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 233}]}, {"term": "Toxicity to various agents", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 233}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 233}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 233}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 233}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 56, "numAtRisk": 233}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 42, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 233}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 469}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 467}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 233}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-US@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M4854", "name": "Benzocaine", "relevance": "LOW"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "T433", "name": "Tannic Acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}